Michael Daugherty1, Dillon Sedaghatpour1, Oleg Shapiro1, Srinivas Vourganti1, Alexander Kutikov2, Gennady Bratslavsky3. 1. Department of Urology, SUNY Upstate Medical University, Syracuse, NY. 2. Department of Surgical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA. 3. Department of Urology, SUNY Upstate Medical University, Syracuse, NY. Electronic address: bratslag@upstate.edu.
Abstract
OBJECTIVE: The influence of histology in metastatic potential is often overlooked when discussing the management options of small renal masses (SRM), with size or growth rate often serving as the triggers for the intervention. We aim to re-examine the definition of a SRM by evaluating the metastatic potential of renal masses incorporating tumor size and histology to create metastatic risk tables. MATERIALS AND METHODS: Surveillance Epidemiology and End Results (SEER)-18 registries database was queried for all cases of clear cell, papillary, and chromophobe renal cell carcinoma (RCC) diagnosed between 2004 and 2012. There were 55,478 cases identified that included 43,783, 8,587, and 3,208 cases of clear cell, papillary, and chromophobe, respectively. Tumors were stratified using 1-cm increments to determine the metastatic potential by calculating the metastatic rate at presentation for different size intervals in histologic categories. RESULTS: For all 3 histologies, tumors measuring 5cm or less had a rate of metastatic RCC at presentation of less than 4%. The metastatic potential was highest for clear cell, followed by papillary and then chromophobe tumors. Setting a cutoff of no more than 3% for metastatic potential to be called a SRM, makes clear cell carcinoma and papillary carcinoma a SRM up to 4cm, whereas the chromophobe RCC would be considered a SRM up to 7cm. CONCLUSION: Although clinical staging and tumor size have been the key determinants in decision-making of patients with solid renal tumors, the histology-specific risks of metastatic potential are different for each mass. The definition of a SRM should be based on the metastatic potential and not on tumor size alone. This information could be helpful for counseling and managing patients with SRMs as well as for modifying active surveillance protocols.
OBJECTIVE: The influence of histology in metastatic potential is often overlooked when discussing the management options of small renal masses (SRM), with size or growth rate often serving as the triggers for the intervention. We aim to re-examine the definition of a SRM by evaluating the metastatic potential of renal masses incorporating tumor size and histology to create metastatic risk tables. MATERIALS AND METHODS: Surveillance Epidemiology and End Results (SEER)-18 registries database was queried for all cases of clear cell, papillary, and chromophobe renal cell carcinoma (RCC) diagnosed between 2004 and 2012. There were 55,478 cases identified that included 43,783, 8,587, and 3,208 cases of clear cell, papillary, and chromophobe, respectively. Tumors were stratified using 1-cm increments to determine the metastatic potential by calculating the metastatic rate at presentation for different size intervals in histologic categories. RESULTS: For all 3 histologies, tumors measuring 5cm or less had a rate of metastatic RCC at presentation of less than 4%. The metastatic potential was highest for clear cell, followed by papillary and then chromophobe tumors. Setting a cutoff of no more than 3% for metastatic potential to be called a SRM, makes clear cell carcinoma and papillary carcinoma a SRM up to 4cm, whereas the chromophobe RCC would be considered a SRM up to 7cm. CONCLUSION: Although clinical staging and tumor size have been the key determinants in decision-making of patients with solid renal tumors, the histology-specific risks of metastatic potential are different for each mass. The definition of a SRM should be based on the metastatic potential and not on tumor size alone. This information could be helpful for counseling and managing patients with SRMs as well as for modifying active surveillance protocols.
Authors: Kyrollis Attalla; Cihan Duzgol; Lily McLaughlin; Jessica Flynn; Irina Ostrovnaya; Paul Russo; Mark H Bilsky; A Ari Hakimi; Nelson S Moss Journal: Urol Oncol Date: 2021-01-07 Impact factor: 3.498
Authors: Thiago Camelo Mourão; Diego Abreu; Gustavo F Carvalhal; Guillermo Gueglio; Walter H da Costa; Vinicius Fernando Calsavara; Luis Meza-Montoya; Rubén G Bengió; Carlos Scorticati; Ricardo Castillejos-Molina; Francisco Rodríguez-Covarrubias; Ana María Autran-Gómez; José Gadu Campos-Salcedo; Alejandro Nolazco; Carlos Ameri; Hamilton Zampolli; Raúl Langenhin; Diego Muguruza; Marcos Tobias Machado; Pablo Mingote; Jorge Clavijo; Lucas Nogueira; Omar Clark; Agustín R Rovegno; Fernando P Secin; Ricardo Decia; Gustavo C Guimarães; Sidney Glina; Oscar Rodríguez-Faba; Joan Palou; Stenio C Zequi Journal: BMC Urol Date: 2020-07-02 Impact factor: 2.264
Authors: Rahul Rajendran; Kevan Iffrig; Deepak K Pruthi; Allison Wheeler; Brian Neuman; Dharam Kaushik; Ahmed M Mansour; Karen Panetta; Sos Agaian; Michael A Liss Journal: Adv Urol Date: 2019-04-23
Authors: Chenghao Zhanghuang; Jinkui Wang; Zhigang Yao; Li Li; Yucheng Xie; Haoyu Tang; Kun Zhang; Chengchuang Wu; Zhen Yang; Bing Yan Journal: Front Public Health Date: 2022-04-04